PIK3CA and breast cancer: Before FAKTION, randomised studies had identified that pan-phosphoinositide 3-kinase (pan-PI3K) and β-sparing inhibitors had unfavourable toxicity profiles and low clinical activity, and these agents were no longer in development as breast cancer therapy.